SymBio PharmaceuticalsSymBio Pharmaceuticals Limited4582東証グロース医薬品FY ending Dec 2025, consolidated, J-GAAP
SymBio Pharmaceuticals brought in ¥2.99B in revenue.
It lost about ¥151 for every ¥100 of sales at the operating level.
Revenue changed +5.3% from the prior year.
FY ending Dec 2019 → FY ending Dec 2020
FY ending Dec 2019 → FY ending Dec 2020
For every ¥100 SymBio Pharmaceuticals sells, how much goes where, and how much is kept.
Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.